argenx SE ARGX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:08 AM EST
282.68quote price arrow down-1.02 (-0.36%)
Volume
393
Close
283.70quote price arrow down-11.21 (-3.80%)
Volume
373,083
52 week range
248.21 - 382.15
Loading...
  • Open293.88
  • Day High294.27
  • Day Low283.51
  • Prev Close283.70
  • 52 Week High382.15
  • 52 Week High Date02/11/21
  • 52 Week Low248.21
  • 52 Week Low Date05/11/21

Key Stats

  • Market Cap14.452B
  • Shares Out50.94M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change-3.53

KEY STATS

  • Open293.88
  • Day High294.27
  • Day Low283.51
  • Prev Close283.70
  • 52 Week High382.15
  • 52 Week High Date02/11/21
  • 52 Week Low248.21
  • 52 Week Low Date05/11/21
  • Market Cap14.452B
  • Shares Out50.94M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta0.96
  • YTD % Change-3.53

RATIOS/PROFITABILITY

  • EPS (TTM)-7.96
  • P/E (TTM)-35.66
  • Fwd P/E (NTM)-15.08
  • EBITDA (TTM)-173.405M
  • ROE (TTM)-13.36%
  • Revenue (TTM)486.97M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-65.38%
  • Debt To Equity (MRQ)0.27%

EVENTS

  • Earnings Date03/03/2022
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On argenx SE

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor...
Peter Verhaeghe
Non-Executive Chairman
Tim Van Hauwermeiren
Chief Executive Officer
Keith Woods
Chief Operating Officer
Karl Gubitz
Chief Financial Officer
Dirk Beeusaert
General Counsel
Address
Willemstraat 5
Breda
4811 AH
Netherlands